NicaPlant, a nicardipine-releasing brain implant that BIT Pharma is developing to treat non-traumatic subarachnoid hemorrhage in patients undergoing surgery, has become the latest product to enter the European Medicines Agency’s PRIME (priority medicines) scheme.
The investigational implant allows for the slow release in situ of nicardipine, a calcium-channel blocker that has been used in...




